-
Lancet oncol: The efficacy of the PARP inhibitor veliparib in the treatment of advanced breast cancer with BRCA mutations.
Time of Update: 2020-09-23
in the BROCADE3 trial, the researchers compared the efficacy of veliparib and placebo combined carbotin and yew alcohol treatment for her2-negative advanced breast cancer patients with BRCA1 or BRCA2 embryonic mutations.
-
The Safety of Veliparib dihydrochloride
Time of Update: 2023-05-11
It is important to take appropriate safety precautions when handling this chemical and to follow proper disposal procedures to prevent harm to the environment.
It is important to take appropriate safety precautions when handling this chemical and to follow proper disposal procedures to prevent harm to the environment.
-
The Production Process of Veliparib dihydrochloride
Time of Update: 2023-05-11
In conclusion, the production process for Veliparib dihydrochloride involves several chemical reactions and purification steps.
In conclusion, the production process for Veliparib dihydrochloride involves several chemical reactions and purification steps.
In conclusion, the production process for Veliparib dihydrochloride involves several chemical reactions and purification steps.
-
The Synthetic Routes of Veliparib dihydrochloride
Time of Update: 2023-05-11
The synthesis of veliparib dihydrochloride is a complex process that involves several steps, including the synthesis of the starting materials, the formation of the intermediate compounds, and the final synthesis of the drug itself.
-
The Instruction of Veliparib dihydrochloride
Time of Update: 2023-05-11
Veliparib dihydrochloride is added to the reaction mixture during the production of these resins in order to catalyze the reaction and help produce the desired end product.
-
The Applications of Veliparib dihydrochloride
Time of Update: 2023-05-11
It is a highly reactive and versatile molecule that can be used in a variety of applications, including as a building block for the synthesis of other chemicals, as a catalyst for chemical reactions, and as a chemical intermediate in the production of a variety of industrial and consumer products.
-
The Upstream and Downstream products of Veliparib dihydrochloride
Time of Update: 2023-05-11
The production process for Veliparib dihydrochloride involves multiple stages, including the extraction of raw materials, the synthesis of intermediate products, and the purification and packaging of the final product.
-
Ann Oncol: Phase III BROCADE3 Study Shows Veliparib (Veliparib) Plus Carboplatin/Paclitaxel After
Time of Update: 2022-03-04
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
-
Clin Cancer Res: PARP inhibitor Veliparib combined with optimized FOLFIRI as a second-line treatment for metastatic pancreatic cancer
Time of Update: 2021-12-24
The study is a randomized phase II trial designed to evaluate the efficacy and safety of mFOLFIRI combined with Veliparib vs FOLFIRI (control: irinotecan, fluorouracil, leucovorin) as a second-line treatment for metastatic pancreatic cancer .
-
J Clin Oncol: Effect of Veliparib combined with carboplatin + paclitaxel chemotherapy as the first
Time of Update: 2021-09-11
OS and PFS in all patientsOS and PFS in all patientsIn the general population, compared with the placebo group, patients in the Veliparib group achieved OS benefits, with a median OS of 12.
-
Clin Cancer Res: Efficacy and safety of PARPi Veliparib combined with carboplatin and etoposide in the treatment of advanced small cell lung cancer
Time of Update: 2021-08-03
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study .
CCR-20-4259Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study in this message
-
-abdominal platinum chemotherapy combined with Veliparib and Beivaczumab
Time of Update: 2020-07-14
Improvements in epithelial ovarian cancer , peritoneal cancer or eOC disease-free survival can only be achieved through improved primary treatment Adding polyADP-ribonucleic inhibitors (PARPi) to a